氨苯砜治疗儿童慢性免疫性血小板减少症:来自印度南部一家三级中心的简短报告
该研究回顾了2012年1月至2016年12月在一家三级中心就诊的103例慢性免疫性血小板减少症(ITP)患儿,其中45例符合纳入标准并接受氨苯砜治疗。早期应答率为37.8%,中位长期随访50个月时至少部分应答率为64.4%。作者认为氨苯砜在儿童慢性ITP中提供良好的初始应答率和持续缓解,与其他可用治疗药物相当。
要点
- 45例接受氨苯砜的慢性ITP患儿中,早期应答率为37.8%。
- 中位随访50个月时,至少部分应答率为64.4%。
- 作者认为氨苯砜的应答率与其他可用治疗药物相当。
核心结论
- 氨苯砜在儿童慢性ITP中提供良好的初始应答率和持续缓解,与其他可用治疗药物相当。
研究设计与样本
- 单中心回顾性研究,2012年1月至2016年12月共诊治103例慢性ITP患儿,其中45例符合纳入标准并接受氨苯砜作为单一二线药物。
主要发现
- 45例接受氨苯砜的患儿中,男孩17例(37.8%),女孩28例(62.2%)。
- 氨苯砜早期应答率为37.8%。
- 中位长期随访时间为50个月,至少部分应答率为64.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) resolves in most children within 3-12 months of diagnosis. Chronic ITP affects 10%-20% of patients, some of whom require treatment. Several second-line agents are efficacious in this group of patients. This paper describes our experience of using dapsone as a single second-line agent in children with chronic ITP. One hundred and three children with chronic ITP were seen at our centre from January 2012 to December 2016. Forty-five children met the inclusion criteria and received dapsone; 17 (37.8%) were boys; and 28 (62.2%) were girls. Early response to dapsone was seen in 37.8% of patients. The median duration of long-term follow-up was 50 months, and at least a partial response was seen in 64.4% of the patients. Dapsone offers good initial response rates and sustained remission in paediatric chronic ITP, comparable to other therapeutic agents available.
引用
- Bharadwaj N, Munireddy J, Selvam S, et al. Dapsone for paediatric chronic immune thrombocytopenia: Short report from a tertiary centre in South India. Br J Haematol. 2024. PMID: 38220217. doi:10.1111/bjh.19277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。